International Journal of Cancer Management

Published by: Kowsar

Immunohistochemistry Study of P53 and C-erbB-2 Expression in Trophoblastic Tissue and Their Predictive Values in Diagnosing Malignant Progression of Simple Molar Pregnancy

Malihe Hasanzadeh 1 , Norrie Sharifi 2 , Marjaneh Farazestanian 3 , Seyed Saman Nazemian 4 and Faezeh Madani Sani 5 , *
Authors Information
1 Department of Obstetrics and Gynecology, Women Health Research Center, Qaem Hospital, Mashhad University of Medical Sciences, Mashhad, IR Iran
2 Department of Pathology, Qaem Hospital, Mashhad University of Medical Sciences, Mashhad, IR Iran
3 Women Health Research Center, Qaem Hospital, Mashhad University of Medical Sciences, Mashhad, IR Iran
4 Emam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, IR Iran
5 Qaem Hospital, Mashhad University of Medical Sciences, Mashhad, IR Iran
Article information
  • Iranian Journal of Cancer Prevention: June 2016, 9 (3); e4115
  • Published Online: June 13, 2016
  • Article Type: Research Article
  • Received: September 22, 2015
  • Revised: December 9, 2015
  • Accepted: June 5, 2016
  • DOI: 10.17795/ijcp-4115

To Cite: Hasanzadeh M, Sharifi N, Farazestanian M, Nazemian S S, Madani Sani F. Immunohistochemistry Study of P53 and C-erbB-2 Expression in Trophoblastic Tissue and Their Predictive Values in Diagnosing Malignant Progression of Simple Molar Pregnancy, Int J Cancer Manag. 2016 ; 9(3):e4115. doi: 10.17795/ijcp-4115.

Abstract
Copyright © 2016, Iranian Journal of Cancer Prevention. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Berkowitz RS, Goldstein DP, Bernstein MR. Evolving concepts of molar pregnancy. J Reprod Med. 1991; 36(1): 40-4[PubMed]
  • 2. Roberts DJ, Mutter GL. Advances in the molecular biology of gestational trophoblastic disease. J Reprod Med. 1994; 39(3): 201-8[PubMed]
  • 3. Szulman AE, Surti U. The syndromes of hydatidiform mole. I. Cytogenetic and morphologic correlations. Am J Obstet Gynecol. 1978; 131(6): 665-71[PubMed]
  • 4. Atrash HK, Hogue CJ, Grimes DA. Epidemiology of hydatidiform mole during early gestation. Am J Obstet Gynecol. 1986; 154(4): 906-9[PubMed]
  • 5. Chun D, Ma HK. Choriocarcinoma in Hong Kong. J R Coll Surg Edinb. 1974; 19(2): 69-81[PubMed]
  • 6. Ma HK, Wong LC. Gestational trophoblastic disease in Hong Kong. Semin Oncol. 1982; 9(2): 224-33[PubMed]
  • 7. Berkowitz RS, Goldstein DP. Current management of gestational trophoblastic diseases. Gynecol Oncol. 2009; 112(3): 654-62[DOI][PubMed]
  • 8. Lurain JR. Gestational trophoblastic tumors. Semin Surg Oncol. 1990; 6(6): 347-53[PubMed]
  • 9. Soper JT. Gestational trophoblastic disease. Obstet Gynecol. 2006; 108(1): 176-87[DOI][PubMed]
  • 10. Benedet JL, Bender H, Jones H, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet. 2000; 70(2): 209-62[PubMed]
  • 11. Clinical Practice Guidelines of Gynecological Cancers by the FIGO Committee on Gynecologic Oncology. 2000;
  • 12. Cheung AN, Srivastava G, Chung LP, Ngan HY, Man TK, Liu YT, et al. Expression of the p53 gene in trophoblastic cells in hydatidiform moles and normal human placentas. J Reprod Med. 1994; 39(3): 223-7[PubMed]
  • 13. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 1991; 253(5015): 49-53[PubMed]
  • 14. Lee YS. p53 expression in gestational trophoblastic disease. Int J Gynecol Pathol. 1995; 14(2): 119-24[PubMed]
  • 15. Yamauchi H, Katayama K, Ueno M, He XJ, Mikami T, Uetsuka K, et al. Essential role of p53 in trophoblastic apoptosis induced in the developing rodent placenta by treatment with a DNA-damaging agent. Apoptosis. 2007; 12(10): 1743-54[DOI][PubMed]
  • 16. Yang X, Zhang Z, Jia C, Li J, Yin L, Jiang S. The relationship between expression of c-ras, c-erbB-2, nm23, and p53 gene products and development of trophoblastic tumor and their predictive significance for the malignant transformation of complete hydatidiform mole. Gynecol Oncol. 2002; 85(3): 438-44[PubMed]
  • 17. Fletcher CD. Diagnostic Histopathology of Tumors. 2007; 2
  • 18. Kumar GL, Rudbeck L, DAKO A. Education Guide: Immunohistochemical Staining Methods: Pathology. 2009;
  • 19. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994; 54(18): 4855-78[PubMed]
  • 20. Efeyan A, Serrano M. p53: guardian of the genome and policeman of the oncogenes. Cell Cycle. 2007; 6(9): 1006-10[DOI][PubMed]
  • 21. Petignat P, Laurini R, Goffin F, Bruchim I, Bischof P. Expression of matrix metalloproteinase-2 and mutant p53 is increased in hydatidiform mole as compared with normal placenta. Int J Gynecol Cancer. 2006; 16(4): 1679-84[DOI][PubMed]
  • 22. Qiao S, Nagasaka T, Harada T, Nakashima N. p53, Bax and Bcl-2 expression, and apoptosis in gestational trophoblast of complete hydatidiform mole. Placenta. 1998; 19(5-6): 361-9[PubMed]
  • 23. Shi YF, Xie X, Zhao CL, Ye DF, Lu SM, Hor JJ, et al. Lack of mutation in tumour-suppressor gene p53 in gestational trophoblastic tumours. Br J Cancer. 1996; 73(10): 1216-9[PubMed]
  • 24. Chen Y, Shen D, Gu Y, Zhong P, Xie J, Song Q. The diagnostic value of Ki-67, P53 and P63 in distinguishing partial Hydatidiform mole from hydropic abortion. Wien Klin Wochenschr. 2012; 124(5-6): 184-7[DOI][PubMed]
  • 25. Chen CA, Chen YH, Chen TM, Ko TM, Wu CC, Lee CN, et al. Infrequent mutation in tumor suppressor gene p53 in gestational trophoblastic neoplasia. Carcinogenesis. 1994; 15(10): 2221-3[PubMed]
  • 26. Fulop V, Mok SC, Genest DR, Gati I, Doszpod J, Berkowitz RS. p53, p21, Rb and mdm2 oncoproteins. Expression in normal placenta, partial and complete mole, and choriocarcinoma. J Reprod Med. 1998; 43(2): 119-27[PubMed]
  • 27. Fulop V, Mok SC, Genest DR, Szigetvari I, Cseh I, Berkowitz RS. c-myc, c-erbB-2, c-fms and bcl-2 oncoproteins. Expression in normal placenta, partial and complete mole, and choriocarcinoma. J Reprod Med. 1998; 43(2): 101-10[PubMed]
  • 28. Kew TY, Bell JA, Pinder SE, Denley H, Srinivasan R, Gullick WJ, et al. c-erbB-4 protein expression in human breast cancer. Br J Cancer. 2000; 82(6): 1163-70[DOI][PubMed]
  • 29. Srinivasan R, Gillett CE, Barnes DM, Gullick WJ. Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers. Cancer Res. 2000; 60(6): 1483-7[PubMed]
  • 30. Bodey B, Bodey BJ, Groger AM, Luck JV, Siegel SE, Taylor CR, et al. Clinical and prognostic significance of the expression of the c-erbB-2 and c-erbB-3 oncoproteins in primary and metastatic malignant melanomas and breast carcinomas. Anticancer Res. 1997; 17(2B): 1319-30[PubMed]
  • 31. Maurer CA, Friess H, Kretschmann B, Zimmermann A, Stauffer A, Baer HU, et al. Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2. Hum Pathol. 1998; 29(8): 771-7[PubMed]
  • 32. Jelincic D, Hudelist G, Singer CF, Bauer M, Horn LC, Bilek K, et al. Clinicopathologic profile of gestational trophoblastic disease. Wien Klin Wochenschr. 2003; 115(1-2): 29-35[PubMed]
  • 33. Yazaki-Sun S, Daher S, de Souza Ishigai MM, Alves MT, Mantovani TM, Mattar R. Correlation of c-erbB-2 oncogene and p53 tumor suppressor gene with malignant transformation of hydatidiform mole. J Obstet Gynaecol Res. 2006; 32(3): 265-72[DOI][PubMed]
  • 34. Cameron B, Gown AM, Tamimi HK. Expression of c-erb B-2 oncogene product in persistent gestational trophoblastic disease. Am J Obstet Gynecol. 1994; 170(6): 1616-21[PubMed]
  • 35. Dehaghani AS, Rad NR, Fattahi MJ, Khadang B, Kashef MA, Sarraf Z, et al. Investigation of soluble HER2 and transforming growth factor Beta-1 serum levels in gestational trophoblastic disease. Pathol Oncol Res. 2009; 15(1): 37-40[DOI][PubMed]
  • 36. Menczer J, Schreiber L, Berger E, Golan A, Levy T. Assessment of Her-2/neu expression in hydatidiform moles for prediction of subsequent gestational trophoblastic neoplasia. Gynecol Oncol. 2007; 104(3): 675-9[DOI][PubMed]
  • 37. Halperin R, Peller S, Sandbank J, Bukovsky I, Schneider D. Expression of the p53 gene and apoptosis in gestational trophoblastic disease. Placenta. 2000; 21(1): 58-62[DOI][PubMed]
  • 38. Hussein MR. Analysis of p53, BCL-2 and epidermal growth factor receptor protein expression in the partial and complete hydatidiform moles. Exp Mol Pathol. 2009; 87(1): 63-9[DOI][PubMed]
  • 39. Enhanced polymer detection system for immunohistochemistry. Laboratory Investigation. : 165
  • 40. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981; 29(4): 577-80[PubMed]
  • 41. Sabattini E, Bisgaard K, Ascani S, Poggi S, Piccioli M, Ceccarelli C, et al. The EnVision++ system: a new immunohistochemical method for diagnostics and research. Critical comparison with the APAAP, ChemMate, CSA, LABC, and SABC techniques. J Clin Pathol. 1998; 51(7): 506-11[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments